Christopher C Benz

List of Publications by Year
in descending order

83 papers	21,681 citations	66234 42 h-index	58464 82 g-index
85 all docs	85 docs citations	85 times ranked	31700 citing authors

#	Article	IF	Citations
1	Integrated genomic characterization of endometrial carcinoma. Nature, 2013, 497, 67-73.	13.7	4,075
2	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, 2018, 173, 400-416.e11.	13.5	2,277
3	Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell, 2018, 173, 321-337.e10.	13.5	2,111
4	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell, 2018, 173, 291-304.e6.	13.5	1,718
5	Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell, 2018, 173, 371-385.e18.	13.5	1,670
6	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell, 2018, 173, 338-354.e15.	13.5	1,417
7	Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. Cell, 2014, 158, 929-944.	13.5	1,242
8	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell, 2018, 33, 676-689.e3.	7.7	750
9	Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Research and Treatment, 1992, 24, 85-95.	1.1	670
10	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell, 2018, 34, 211-224.e6.	7.7	623
11	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell, 2018, 33, 690-705.e9.	7.7	478
12	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell, 2018, 33, 721-735.e8.	7.7	396
13	Breast Cancer Growth Prevention by Statins. Cancer Research, 2006, 66, 8707-8714.	0.4	309
14	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell, 2018, 173, 305-320.e10.	13.5	272
15	Ageing, oxidative stress and cancer: paradigms in parallax. Nature Reviews Cancer, 2008, 8, 875-879.	12.8	249
16	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports, 2018, 23, 194-212.e6.	2.9	245
17	Enhanced NFÎºB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer, 2007, 7, 59.	1.1	175
18	A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Research, 2010, 12, R85.	2.2	175

#	Article	IF	Citations
19	Impact of aging on the biology of breast cancer. Critical Reviews in Oncology/Hematology, 2008, 66, 65-74.	2.0	165
20	ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis. Oncogene, 1997, 14, 1617-1622.	2.6	159
21	Tyrosine Kinase Inhibitors Targeted to the Epidermal Growth Factor Receptor Subfamily. Drugs, 2000, 59, 753-767.	4.9	152
22	Stress Response Protein (srp-27) Determination in Primary Human Breast Carcinomas: Clinical, Histologic, and Prognostic Correlations. Journal of the National Cancer Institute, 1991, 83, 170-178.	3.0	150
23	HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene, 1997, 15, 1513-1525.	2.6	147
24	Activation of nuclear factor-ÎºB (NFÎºB) identifies a high-risk subset of hormone-dependent breast cancers. International Journal of Biochemistry and Cell Biology, 2005, 37, 1130-1144.	1.2	123
25	Protein Acetylation and Histone Deacetylase Expression Associated with Malignant Breast Cancer Progression. Clinical Cancer Research, 2009, 15, 3163-3171.	3.2	110
26	PARADIGM-SHIFT predicts the function of mutations in multiple cancers using pathway impact analysis. Bioinformatics, 2012, 28, i640-i646.	1.8	94
27	Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype. Scientific Reports, 2018, 8, 2410.	1.6	93
28	Age-associated biomarker profiles of human breast cancer. International Journal of Biochemistry and Cell Biology, 2002, 34, 1318-1330.	1.2	90
29	ErbB2 Trafficking and Degradation Associated with K48 and K63 Polyubiquitination. Cancer Research, 2010, 70, 3709-3717.	0.4	89
30	Prognostic and Predictive Significance of ErbB-2 Breast Tumor Levels Measured by Enzyme Immunoassay. Journal of Clinical Oncology, 2001, 19, 645-656.	0.8	85
31	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. Cell Reports, 2018, 23, 213-226.e3.	2.9	83
32	A Role for Both Ets and C/EBP Transcription Factors and mRNA Stabilization in the MAPK-dependent Increase in p21^{Cip-1/WAF1/mda6}Protein Levels in Primary Hepatocytes. Molecular Biology of the Cell, 2000, 11, 2915-2932.	0.9	73
33	Ets regulation of the erbB2 promoter. Oncogene, 2000, 19, 6490-6502.	2.6	68
34	Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. Breast Cancer Research, 2007, 9, R59.	2.2	64
35	Sources of superoxide/H2O2 during mitochondrial proline oxidation. Redox Biology, 2014, 2, 901-909.	3.9	62
36	Age-Dependent Changes in Breast Cancer Hormone Receptors and Oxidant Stress Markers. Breast Cancer Research and Treatment, 2002, 76, 221-236.	1.1	60

#	Article	IF	Citations
37	Preferential Oxidation of Zinc Finger 2 in Estrogen Receptor DNA-binding Domain Prevents Dimerization and, Hence, DNA Bindingâ€. Biochemistry, 2000, 39, 8406-8417.	1.2	57
38	Oxidant stress impaired DNA-binding of estrogen receptor from human breast cancer. Molecular and Cellular Endocrinology, 1998, 146, 151-161.	1.6	55
39	Destabilization of ERBB2 Transcripts by Targeting 3â€² Untranslated Region Messenger RNA Associated HuR and Histone Deacetylase-6. Molecular Cancer Research, 2008, 6, 1250-1258.	1.5	54
40	Expression of a truncated 100â€‰kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. Oncogene, 2001, 20, 2101-2111.	2.6	53
41	Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. Molecular Cancer Therapeutics, 2002, 1, 385-92.	1.9	44
42	mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms. Breast Cancer Research and Treatment, 2014, 144, 287-298.	1.1	42
43	ErbB2 Activation of ESX gene expression. Oncogene, 2002, 21, 3934-3938.	2.6	35
44	RPL24: a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth. Oncotarget, 2014, 5, 5165-5176.	0.8	34
45	DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas. Npj Breast Cancer, 2016, 2, 16007.	2.3	33
46	Oxidant-sensitive protein phosphorylation in endothelial cells. Free Radical Biology and Medicine, 1994, 16, 771-777.	1.3	32
47	Redox Control of Zinc Finger Proteins. Methods in Enzymology, 2002, 353, 54-69.	0.4	31
48	Vitamin K3 (Menadione)-Induced Oncosis Associated with Keratin 8 Phosphorylation and Histone H3 Arylation. Molecular Pharmacology, 2005, 68, 606-615.	1.0	30
49	Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers. Breast Cancer Research and Treatment, 2011, 126, 803-810.	1.1	29
50	Targeting of Liposomes to Solid Tumors: The Case of Sterically Stabilized Anti-Her2 Immunoliposomes. Journal of Liposome Research, 1997, 7, 391-417.	1.5	28
51	An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk. Breast Cancer Research, 2013, 15, R103.	2.2	28
52	Exon 4-encoded acidic domain in the epithelium-restricted Ets factor, ESX, confers potent transactivating capacity and binds to TATA-binding protein (TBP). Oncogene, 1999, 18, 3682-3695.	2.6	26
53	Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition. Molecular Cancer Therapeutics, 2019, 18, 1374-1385.	1.9	26
54	Reactivity of zinc finger cysteines: Chemical modifications within labile zinc fingers in estrogen receptor. Journal of the American Society for Mass Spectrometry, 2005, 16, 2017-2026.	1.2	23

#	Article	IF	Citations
55	Tumor labeling indices of primary breast cancers and their regional lymph node metastases. Cancer, 1993, 71, 3914-3919.	2.0	22
56	Polyamine inhibition of estrogen receptor (ER) DNA-binding and ligand-binding functions. Breast Cancer Research and Treatment, 1998, 48, 243-257.	1.1	19
57	Targeting of Drugs to Solid Tumors Using Anti-Her2 Immunoliposomes. Journal of Liposome Research, 1998, 8, 425-442.	1.5	19
58	Novel Pathways Associated with Quinone-Induced Stress in Breast Cancer Cells. Drug Metabolism Reviews, 2006, 38, 601-613.	1.5	19
59	First pregnancy events and future breast density: modification by age at first pregnancy and specific VEGF and IGF1R gene variants. Cancer Causes and Control, 2014, 25, 859-868.	0.8	19
60	Recent trends in hormone therapy utilization and breast cancer incidence rates in the high incidence population of Marin County, California. BMC Public Health, 2010, 10, 228.	1.2	17
61	Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?. Breast Cancer Research and Treatment, 2012, 136, 693-703.	1.1	15
62	Clinical Pharmacokinetics of Drugs Used in the Treatment of Breast Cancer. Clinical Pharmacokinetics, 1988, 15, 180-193.	1.6	14
63	Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden. JAMA Network Open, 2021, 4, e2114716.	2.8	14
64	Essential cysteine-alkylation strategies to monitor structurally altered estrogen receptor as found in oxidant-stressed breast cancers. Analytical Biochemistry, 2003, 320, 21-31.	1.1	13
65	Hyperplasia, reduced E-cadherin expression, and developmental arrest in mammary glands oxidatively stressed by loss of mitochondrial superoxide dismutase. Breast, 2005, 14, 256-263.	0.9	13
66	Validated High-Throughput Screening of Drug-Like Small Molecules for Inhibitors of ErbB2 Transcription. Assay and Drug Development Technologies, 2006, 4, 273-284.	0.6	12
67	A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population. Breast Cancer Research, 2020, 22, 81.	2.2	12
68	Assessment of 25-Year Survival of Women With Estrogen Receptorâ€“Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy. JAMA Network Open, 2021, 4, e2114904.	2.8	12
69	ERpS294 is a biomarker of ligand or mutational ERÎ± activation and a breast cancer target for CDK2 inhibition. Oncotarget, 2017, 8, 83432-83445.	0.8	11
70	<scp>DGCR</scp> 8 is essential for tumor progression following <scp>PTEN</scp> loss in the prostate. EMBO Reports, 2015, 16, 1219-1232.	2.0	9
71	Functional IGF1R variant predicts breast cancer risk in women with preeclampsia in California Teachers Study. Cancer Causes and Control, 2017, 28, 1027-1032.	0.8	9
72	Altered promoter usage characterizes monoallelic transcription arising withERBB2 amplification in human breast cancers. Genes Chromosomes and Cancer, 2006, 45, 983-994.	1.5	8

#	Article	IF	Citations
73	FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index. Breast Cancer Research and Treatment, 2015, 154, 23-32.	1.1	8
74	Clinical and molecular characteristics of estrogen receptorâ€positive ultralow risk breast cancer tumors identified by the 70â€gene signature. International Journal of Cancer, 2022, 150, 2072-2082.	2.3	7
75	Pregnancy Hypertension and a Commonly Inherited IGF1R Variant (rs2016347) Reduce Breast Cancer Risk by Enhancing Mammary Gland Involution. Journal of Oncology, 2019, 2019, 1-8.	0.6	6
76	N-Propargylglycine: a unique suicide inhibitor of proline dehydrogenase with anticancer activity and brain-enhancing mitohormesis properties. Amino Acids, 2021, 53, 1927-1939.	1.2	5
77	Geographic excess of estrogen receptor-positive breast cancer. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 1523-7.	1.1	5
78	A steroid metabolizing gene variant in a polyfactorial model improves risk prediction in a high incidence breast cancer population. BBA Clinical, 2014, 2, 94-102.	4.1	4
79	Discovery of internalizing antibodies to basal breast cancer cells. Protein Engineering, Design and Selection, 2018, 31, 17-28.	1.0	4
80	Cancer and Cardiovascular Risk in Women With Hypertensive Disorders of Pregnancy Carrying a Common IGF1R Variant. Mayo Clinic Proceedings, 2020, 95, 2684-2696.	1.4	3
81	Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer. Breast Cancer Research and Treatment, 2022, 191, 451-458.	1.1	2
82	Devious signals from NFÎºB driving breast cancer progression. Breast Cancer Online: BCO, 2005, 8, .	0.1	0
83	Targeting Molecular Aberrations in Breast Cancer: Is It about Time?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 186-191.	1.8	0